The MEST score provides earlier risk prediction in lgA nephropathy. - Wikidata - awgldk - TriplyDB

The MEST score provides earlier risk prediction in lgA nephropathy.

The MEST score provides earlier risk prediction in lgA nephropathy.

http://www.wikidata.org/entity/Q35892267

about

Tubular atrophy/interstitial fibrosis scores of Oxford classification combinded with proteinuria level at biopsy provides earlier risk prediction in lgA nephropathy.Increased C4 and decreased C3 levels are associated with a poor prognosis in patients with immunoglobulin A nephropathy: a retrospective study Comparison of different normalization strategies for the analysis of glomerular microRNAs in IgA nephropathy.Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years: a case-control study Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection Corticosteroids in IgA Nephropathy: Lessons from Recent Studies.Markers for the progression of IgA nephropathy.Biomarkers and targeted new therapies for IgA nephropathy.Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients.Is there a role for immunosuppression in immunoglobulin A nephropathy?Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.NLRP3 Localizes to the Tubular Epithelium in Human Kidney and Correlates With Outcome in IgA Nephropathy Remission of Hematuria Improves Renal Survival in IgA Nephropathy.Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy.Elevated serum fibrinogen level is an independent risk factor for IgA nephropathy.IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology.The clinical relevance of plasma CD147/basigin in biopsy-proven kidney diseases.Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty.Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy.IgA Nephropathy.Glomerular disease: Updated Oxford Classification of IgA nephropathy: a new MEST-C score.Con: STOP immunosuppression in IgA nephropathy.IgA Nephropathy: A European Perspective in the Corticosteroid Treatment The Emerging Role of Pathogenesis of IgA Nephropathy

P2860

Q33683223-F929DEB0-6680-431A-A886-C74E0072665E Q33893355-30708EB1-FA27-4A10-BA56-73E4F9641819 Q36110820-BCAC4984-9378-44AD-AA17-68C899D95BA9 Q36243259-E488517F-7A3F-4E8F-99E4-BA7B23AB8CA8 Q36307746-82377AD5-DF4E-4F51-8A42-6C7449E7ACD6 Q38817381-CCE18FEA-2E3D-4E38-9493-6986E94143A2 Q38824816-6ECF74DB-BAF6-47C2-BCDA-4DA7EAD468F6 Q38871090-5C9D0507-3B8D-42AC-99D3-D932778120D3 Q38999373-C6A53B5F-1D5D-4A61-8589-2D603F0D4928 Q39229309-01A14B40-9B29-41F1-8C63-30DCE6DEFFE3 Q39457194-74974980-1A24-4336-97D3-76BB0E6403F0 Q39839285-DF36BDDC-1EE0-4F9F-BE1E-ED3A01E5915C Q40168439-7B52841E-2D39-4990-8F42-10AC775C6B99 Q40456075-43FAB7E5-7AA7-49D1-B2C6-223C30509E03 Q43924057-2126F03D-8275-4BD9-80B7-D06E7BAE351C Q47100563-64852266-6CE0-4FE8-8F8E-022B985F3B27 Q49477908-18636FD1-166D-4A0F-87DB-BB68317BA5D3 Q49874313-2E278B17-580D-4D99-BF88-AD6C02357657 Q51734842-38086704-068B-4599-95E0-C01EFE938C62 Q51758616-C7ABEFBD-1CF5-4955-8797-A2D8D2EBB953 Q51834649-E06AAF53-5D5A-45CE-9D8D-2210DD0CF25E Q53278365-30104125-4C1B-4FEA-8008-2DC0D4B08146 Q53556768-AFC8E6E7-8FBB-40F4-9C97-2014742A4E23 Q57100792-6CFD28D4-B732-4834-94DA-3A61C9875CF9 Q58734688-779A5758-ABED-4F16-8F0E-40A287093BEC

P2860

The MEST score provides earlier risk prediction in lgA nephropathy.

http://www.wikidata.org/entity/Q35892267

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The MEST score provides earlier risk prediction in lgA nephropathy.

@ast

The MEST score provides earlier risk prediction in lgA nephropathy.

@en

type

label

The MEST score provides earlier risk prediction in lgA nephropathy.

@ast

The MEST score provides earlier risk prediction in lgA nephropathy.

@en

prefLabel

The MEST score provides earlier risk prediction in lgA nephropathy.

@ast

The MEST score provides earlier risk prediction in lgA nephropathy.

@en

P1433

Q35892267-896C74B0-988B-4543-83D3-046FD6A2819F

P1476

Q35892267-E518BF21-EC40-4460-B168-695BECCE441C

P2093

Q35892267-23D0B493-C686-433A-A79D-75CEDE374B27

Q35892267-3D81FB2F-E683-41CC-B8F8-2EE2221338E5

Q35892267-5B0B6D2E-59C0-48A7-81D6-302931C14F92

Q35892267-5C06D5EF-6399-4BAE-ACBC-5A39717F96A5

Q35892267-6423FB2E-42D1-41AB-9627-4F712790BA0E

Q35892267-66AA1890-4220-4C8B-AF6A-D24842CAABD8

Q35892267-797ECC34-6EE6-4D04-86A9-CB1C7830E9B8

Q35892267-8A7C2EEB-27AE-4A5E-AB62-8358F718DAE5

Q35892267-BB276F45-0C27-469A-A33A-F9B6BA066C95

Q35892267-BEACC286-0F3B-4AEB-9018-E9FDB1A1A000

P2888

Q35892267-9F9F87BF-9349-4244-8D71-FA1B3F2A81FC

P304

Q35892267-721F5F55-3224-4831-965F-ED8EB27FF2A8

P31

Q35892267-D41E6D4E-452C-4F64-BFC9-40A5DFF0F06B

P356

Q35892267-70E9A1D2-CB3E-4F80-AA21-05534429FEC9

P407

Q35892267-1BF8291B-D086-41B5-86DC-E3C22848BA46

P433

Q35892267-FE693BD6-8515-4505-8C76-5FA936B73541

P478

Q35892267-A1C5190E-E0AB-4410-8ECB-17EE775A07D3

P577

Q35892267-152588F0-AA25-45E2-BECA-D0426D863AF1

P698

Q35892267-9EA52A04-F691-4898-843D-2438FD9B0FA7

P356

P1433

Kidney International

P1476

The MEST score provides earlier risk prediction in lgA nephropathy.

@en

P2093

Andrew M Herzenberg

http://www.w3.org/2001/XMLSchema#string

Daniel C Cattran

http://www.w3.org/2001/XMLSchema#string

Gabriela Espino-Hernandez

http://www.w3.org/2001/XMLSchema#string

Heather N Reich

http://www.w3.org/2001/XMLSchema#string

Ian S D Roberts

http://www.w3.org/2001/XMLSchema#string

John Feehally

http://www.w3.org/2001/XMLSchema#string

Oxford Derivation North American Validation and VALIGA Consortia

http://www.w3.org/2001/XMLSchema#string

Oxford Derivation, North American Validation and VALIGA Consortia

http://www.w3.org/2001/XMLSchema#string

Rosanna Coppo

http://www.w3.org/2001/XMLSchema#string

Sean J Barbour

http://www.w3.org/2001/XMLSchema#string

P2888

P304

167-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/KI.2015.322

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26759049

http://www.w3.org/2001/XMLSchema#string